BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38177052)

  • 1. Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer.
    Ulaner GA; Vaz SC; Groheux D
    PET Clin; 2024 Apr; 19(2):147-162. PubMed ID: 38177052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
    Ulaner GA; Vaz SC
    Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [
    Azad GK; Taylor BP; Green A; Sandri I; Swampillai A; Harries M; Kristeleit H; Mansi J; Goh V; Cook GJR
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):821-830. PubMed ID: 30506455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
    Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
    Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV
    Azad GK; Cousin F; Siddique M; Taylor B; Goh V; Cook GJR
    Mol Imaging Biol; 2019 Aug; 21(4):781-789. PubMed ID: 30250989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET Imaging for Breast Cancer.
    Fowler AM; Cho SY
    Radiol Clin North Am; 2021 Sep; 59(5):725-735. PubMed ID: 34392915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-individual comparison of
    Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound.
    Avery R; Kuo PH
    Clin Nucl Med; 2013 Sep; 38(9):746-8. PubMed ID: 23797230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of PET Tracers in Molecular Imaging for Breast Cancer.
    Boers J; de Vries EFJ; Glaudemans AWJM; Hospers GAP; Schröder CP
    Curr Oncol Rep; 2020 Jul; 22(8):85. PubMed ID: 32627087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Study of Serial
    Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM
    J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of bone metastases in breast cancer by positron emission tomography.
    Schirrmeister H
    Radiol Clin North Am; 2007 Jul; 45(4):669-76, vi. PubMed ID: 17706531
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT].
    Moragas M; Soler M; Riera E; García JR
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
    Hillner BE; Siegel BA; Hanna L; Duan F; Quinn B; Shields AF
    J Nucl Med; 2015 Feb; 56(2):222-8. PubMed ID: 25593113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of bone-seeking novel radiotracer
    Passah A; Tripathi M; Ballal S; Yadav MP; Kumar R; Roesch F; Meckel M; Sarathi Chakraborty P; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):41-49. PubMed ID: 27455986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.